Prospera Financial Services Inc Purchases 4,238 Shares of AbbVie Inc. $ABBV

Prospera Financial Services Inc increased its position in AbbVie Inc. (NYSE:ABBV) by 4.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 93,424 shares of the company’s stock after purchasing an additional 4,238 shares during the quarter. Prospera Financial Services Inc’s holdings in AbbVie were worth $21,648,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in ABBV. Windle Wealth LLC boosted its stake in shares of AbbVie by 0.9% in the 3rd quarter. Windle Wealth LLC now owns 43,074 shares of the company’s stock valued at $9,973,000 after purchasing an additional 386 shares during the last quarter. Midwest Financial Group LLC bought a new stake in AbbVie in the third quarter valued at about $247,000. Oppenheimer & Co. Inc. lifted its stake in AbbVie by 3.5% in the third quarter. Oppenheimer & Co. Inc. now owns 167,541 shares of the company’s stock valued at $38,792,000 after buying an additional 5,688 shares during the period. Linden Thomas Advisory Services LLC grew its position in shares of AbbVie by 1.2% during the 3rd quarter. Linden Thomas Advisory Services LLC now owns 13,100 shares of the company’s stock worth $3,033,000 after buying an additional 152 shares during the period. Finally, Western Wealth Management LLC increased its stake in shares of AbbVie by 0.4% in the 3rd quarter. Western Wealth Management LLC now owns 21,829 shares of the company’s stock valued at $5,054,000 after acquiring an additional 85 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ABBV has been the subject of a number of recent analyst reports. Berenberg Bank set a $275.00 price objective on AbbVie in a research note on Tuesday, January 20th. Evercore dropped their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Morgan Stanley boosted their price target on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Price Performance

Shares of NYSE ABBV opened at $223.00 on Tuesday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The stock has a market capitalization of $394.13 billion, a PE ratio of 94.49, a P/E/G ratio of 0.85 and a beta of 0.35. The business has a fifty day moving average price of $223.71 and a two-hundred day moving average price of $220.07.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the firm posted $2.16 EPS. The company’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.